PH12022551495A1 - Improved process for culturing tumor-infiltrating lymphocytes for therapeutic use - Google Patents

Improved process for culturing tumor-infiltrating lymphocytes for therapeutic use

Info

Publication number
PH12022551495A1
PH12022551495A1 PH1/2022/551495A PH12022551495A PH12022551495A1 PH 12022551495 A1 PH12022551495 A1 PH 12022551495A1 PH 12022551495 A PH12022551495 A PH 12022551495A PH 12022551495 A1 PH12022551495 A1 PH 12022551495A1
Authority
PH
Philippines
Prior art keywords
infiltrating lymphocytes
therapeutic use
improved process
tumor
tils
Prior art date
Application number
PH1/2022/551495A
Other languages
English (en)
Inventor
Ulrik Cordes
Christina Friese
Christina Heeke
Nikolaj Kirketerp-Mã˜Ller
Original Assignee
Cbio As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cbio As filed Critical Cbio As
Publication of PH12022551495A1 publication Critical patent/PH12022551495A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/231—Interleukin-10 (IL-10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PH1/2022/551495A 2019-12-18 2020-12-18 Improved process for culturing tumor-infiltrating lymphocytes for therapeutic use PH12022551495A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19217356 2019-12-18
PCT/EP2020/087151 WO2021123255A1 (en) 2019-12-18 2020-12-18 Improved process for culturing tumor-infiltrating lymphocytes for therapeutic use

Publications (1)

Publication Number Publication Date
PH12022551495A1 true PH12022551495A1 (en) 2023-11-13

Family

ID=68944537

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/551495A PH12022551495A1 (en) 2019-12-18 2020-12-18 Improved process for culturing tumor-infiltrating lymphocytes for therapeutic use

Country Status (14)

Country Link
US (1) US20230018646A1 (enExample)
EP (1) EP4077640B1 (enExample)
JP (2) JP2023509388A (enExample)
KR (1) KR20220119080A (enExample)
CN (1) CN114929861A (enExample)
AU (1) AU2020408201A1 (enExample)
BR (1) BR112022011702A2 (enExample)
CA (1) CA3161510A1 (enExample)
DK (1) DK4077640T3 (enExample)
ES (1) ES2984777T3 (enExample)
IL (1) IL293874B2 (enExample)
MX (1) MX2022007416A (enExample)
PH (1) PH12022551495A1 (enExample)
WO (1) WO2021123255A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12365871B2 (en) 2020-04-28 2025-07-22 Lyell Immunopharma, Inc. Methods for culturing cells
CN116421720A (zh) * 2023-04-26 2023-07-14 乔国梁 抗肿瘤联用细胞产品和抗肿瘤细胞产品
CN118853565A (zh) * 2024-09-14 2024-10-29 青岛华赛伯曼医学细胞生物有限公司 一种肿瘤浸润淋巴细胞的培养工艺

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103374548A (zh) * 2012-04-27 2013-10-30 上海诺昊亚医学诊断技术有限公司 一种肿瘤浸润淋巴细胞的高效扩增培养液
US20170044496A1 (en) * 2014-04-10 2017-02-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
GB2573406B (en) * 2016-10-18 2021-11-10 Univ Minnesota Tumor infiltrating lymphocytes and methods of therapy
TWI826360B (zh) * 2016-11-17 2023-12-21 美商艾歐凡斯生物治療公司 殘餘腫瘤浸潤性淋巴細胞及製備和使用彼之方法
WO2019086711A1 (en) * 2017-11-06 2019-05-09 Ludwig Institute For Cancer Research Ltd Method for expansion of lymphocytes

Also Published As

Publication number Publication date
CA3161510A1 (en) 2021-06-24
EP4077640B1 (en) 2024-05-08
CN114929861A (zh) 2022-08-19
DK4077640T3 (da) 2024-07-29
US20230018646A1 (en) 2023-01-19
IL293874B2 (en) 2024-03-01
JP2023509388A (ja) 2023-03-08
WO2021123255A1 (en) 2021-06-24
KR20220119080A (ko) 2022-08-26
IL293874A (en) 2022-08-01
BR112022011702A2 (pt) 2022-09-06
MX2022007416A (es) 2022-09-19
AU2020408201A1 (en) 2022-07-14
JP2024175144A (ja) 2024-12-17
ES2984777T3 (es) 2024-10-31
EP4077640A1 (en) 2022-10-26
IL293874B1 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
US20210030794A1 (en) Gamma delta t cells and uses thereof
Smith et al. Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno‐free CTS immune cell serum replacement
Zuliani et al. Value of large scale expansion of tumor infiltrating lymphocytes in a compartmentalised gas-permeable bag: interests for adoptive immunotherapy
WO2020033927A3 (en) Processes for generating engineered cells and compositions thereof
EP4495133A3 (en) Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
MX2022012409A (es) Celulas que presentan antigeno artificial manipulado por ingenieria para expansion linfocitica infiltrante de tumores.
RU2010125605A (ru) Антитело против глипикана-3 с улучшенными кинетическими показателями в плазме
EP4289944A3 (en) Method for preparing genetically-modified t cells which express chimeric antigen receptor
MY180750A (en) Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
Raber et al. T cells conditioned with MDSC show an increased anti-tumor activity after adoptive T cell based immunotherapy
Cooper et al. Rapid GMP-compliant expansion of SARS-CoV-2–specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19
Salnikov et al. The viral etiology of EBV-associated gastric cancers contributes to their unique pathology, clinical outcomes, treatment responses and immune landscape
AR094389A1 (es) USO DE INHIBIDORES DE iNOS PARA AUMENTAR EL RENDIMIENTO VÍRICO EN CULTIVOS
WO2019053003A1 (en) METHODS FOR ENHANCING RNA EXPRESSION IN CELL
WO2021101273A3 (ko) 조절 t 세포 배양용 조성물 및 이의 용도
JPWO2020027094A1 (ja) ｉＰＳ細胞を介して再生Ｔ細胞集団を製造する方法
JP2022529687A (ja) Ｅｂｖ特異的免疫細胞
MX2022007416A (es) Proceso mejorado para el cultivo de linfocitos infiltrantes de tumor para uso terapeutico.
Lin et al. Optimizing the procedure for manufacturing clinical-grade genetically manipulated natural killer cells for adoptive immunotherapy
NZ788176A (en) Medium composition for culturing t cells and method for culturing t cells using same
WO2021015615A8 (en) Low density cell culture
X-Lan et al. Suppression of EBNA1 expression inhibits growth of EBV-positive NK/T cell lymphoma cells
MY199770A (en) Method for culturing cord blood-derived natural killer cells using transformed t cells
IN2015KN00569A (enExample)
Zhang et al. Impact of connexin 43 coupling on survival and migration of multiple myeloma cells